BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO is approved for use in individuals aged 10 through 25 years.
Approval of BEXSERO is based on demonstration of immune response, as measured by serum bactericidal activity against three serogroup B strains representative of prevalent strains in the United States. The effectiveness of BEXSERO against diverse serogroup B strains has not been confirmed.
What is the MenB vaccination rate of your practice?
Be sure to check your records—the numbers may be lower than you think. According to 2019 CDC survey data, only 21.8% of 17-year-olds received at least 1 dose of a MenB vaccine.4
Start the series. Stay the course.
Do your patients receive both doses? Take these important steps to ensure they complete the series:
- Schedule the second dose appointment as soon as your patient receives the first dose
- Set up follow-up reminders to help patients stay on track
- Click here to sign up for the GSK Vaccine Reminder Service for MenB
CDC=Centers for Disease Control and Prevention; MenB=meningococcal serogroup B.